Clinical Trials Logo

Filter by:
NCT ID: NCT05681793 Completed - Depression Clinical Trials

Survey on the Clinical Assessment of the Psychological Status of a Patient Over 75 Years Old in Oncology During the Realization of the G8 Score (CADEPO)

CADEPO
Start date: January 17, 2023
Phase:
Study type: Observational

The goal of this observational study is to make a statement concerning the identification of depressive symptoms at the time of the realization of the G8 score in patients over 75 with cancer and followed in oncology. The main question it aims to answer are: - Compare the medical hetero-evaluation of depressive symptoms via the G8 "neuro-psychiatric disorders" item score with a self-evaluation via the GDS-15 score - Evaluate the number of patients over 75 treated with antidepressants - Evaluate the proportion of patients with depressive symptoms according to the predisposing factors - Compare the number of patients followed in oncogeriatrics over the period from 01/01/2022 to 02/28/2022 and the period from 01/01/2023 to 02/28/2023 Participants will complete a self-questionnaire (GDS-15 score) as well as a socio-demographic sheet.

NCT ID: NCT05681741 Completed - Clinical trials for Cardiopulmonary Bypass

Impact of Cardiopulmonary Bypass Flow on Cerebral Autoregulation

FLOWMAPCA
Start date: January 8, 2023
Phase: N/A
Study type: Interventional

Cerebral autoregulation is defined by the capacity of the brain to maintain a constant cerebral blood flow (CBF) despite variations of arterial pressure. However, when the arterial pressure is below a critical threshold, cerebral blood decreases. This critical threshold is called the lower limit of cerebral autoregulation (LLA). Cardiopulmonary bypass is a unique environment wherein systemic blood flow is totally controlled by the cardiopulmonary bypass pump. High pump flows combined with low arterial pressures has been shown to not compromise neurologic postoperative outcomes. Our hypothesis is that that LLA may depend on the cardiopulmonary bypass flow, ie the LLA may decrease when the cardiopulmonary bypass flow increases, explaining why low arterial pressure may be well tolerated.

NCT ID: NCT05681572 Recruiting - Anesthesia Clinical Trials

Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia

pediaPREM
Start date: April 18, 2023
Phase: Phase 3
Study type: Interventional

Children undergoing general anesthesia for surgery commonly need sedative and anxiolytic premedication but little clinical evidence supports is benefit for children older than 7 years old. The aim of this prospective randomized clinical trial is to assess the impact of pharmacologic premedication on perioperative children experience.

NCT ID: NCT05681533 Recruiting - Diabetic Patients Clinical Trials

Epicardial Adipose Tissue and Arterial Stiffness in People Living With Diabetes (METAB-CV-PWV)

METAB-CV-PWV
Start date: March 31, 2021
Phase:
Study type: Observational

The present study is a retrospective and prospective current care cohort that will allow us to evaluate the relationship between epicardial fat volume and increased arterial stiffness in a person living with diabetes.

NCT ID: NCT05681442 Recruiting - Sepsis Clinical Trials

Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis

BICCS
Start date: November 13, 2023
Phase: Phase 4
Study type: Interventional

Patients hospitalized in ICU with sepsis (infection with life-threatening organ dysfunction according to sepsis 3.0 definitions) or septic shock presumably due to MDR-GNB (multidrug resistant Gram-negative bacteria). The study will be a prospective multicentre, randomized, open-label comparative continuous vs. intermittent pivotal βL (Beta Lactamine) antibiotic infusion strategies and combination vs. monotherapy trial conducted with a 2X2 factorial design.

NCT ID: NCT05681351 Recruiting - Clinical trials for Severe Hypertriglyceridemia

A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Start date: December 13, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

NCT ID: NCT05680818 Recruiting - Clinical trials for Autosomal Dominant Hypocalcemia (ADH)

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

CALIBRATE
Start date: January 6, 2023
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

NCT ID: NCT05680259 Recruiting - Pain Clinical Trials

Assessment of the Effects of Maela Connected Follow-up on Well-being and Pain After Lumbar Spine Surgery

HOSPITEL
Start date: October 6, 2022
Phase: N/A
Study type: Interventional

Digital technologies could reduce the length of hospital stay and improve post-operative recuperation after discharge by offering a remote follow-up. No study has investigated the effects of connected follow-up on lumbar spine inpatients. The purpose of this project is to assess the effects of connected follow-up on pain and quality of life after lumbar spine surgery.

NCT ID: NCT05680181 Completed - Clinical trials for Molluscum Contagiosum

Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin

SERENITE
Start date: January 20, 2023
Phase:
Study type: Observational

Molutrex® a 5% potassium hydroxide solution for topical application to the skin. Molutrex® is intended for the superficial treatment of certain types of warts, molluscum contagiosum and is composed of potassium hydroxide (5%) purified water. With regard to the 2017/745 RDM, he is a class IIa medical device. In accordance with Regulation (EU) 2017/745 of the European Parliament and of the Council of April 5, 2017 relating to medical devices, as part of the Molutrex® Post-Marketing Monitoring Plan, the objective of this study is to have data on the performance , safety and suitability for real-life use of Molutrex® in a prospective cohort of patients with molluscum contagiosum. Since molluscum contagiosum is most prevalent in children, and potassium hydroxide is used very little in adults (because most often they are immunocompromised patients requiring other antiviral treatments), the study will be conducted in children aged 2 to 10 years. This population represents the majority of patients treated with Molutrex®, although the product can be used in adults. The study includes 2 visits, the objective of the study being to evaluate the percentage of children healed at 45 days, healing defined by a reduction of more than 90% in the number of lesions present at inclusion in the study.

NCT ID: NCT05679544 Recruiting - Clinical trials for Metabolic Disturbance

Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs

PAH-ProMetGen
Start date: April 25, 2023
Phase: N/A
Study type: Interventional

This research project aims at better understanding the early biological effects resulting from occupational exposure to complex Polycyclic Aromatic Hydrocarbon (PAH) mixtures. Current biomarkers used as part of biomonitoring campaigns are biomarkers of exposure, not numerous and poorly related to health effects. The aim of this study is thus to improve our understanding of biological consequences of such exposures, both in terms of proteins deregulation, metabolism deregulation and genotoxicity.